- Open Access
Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
Journal of Translational Medicine volume 15, Article number: 60 (2017)
Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available.
A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin reference population were also performed. For the total study cohort the age range was 18–65 years with a female: male participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference intervals.
Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. All routine and special pathology markers were within the normal laboratory reference intervals for the total study cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma.
Elevated activin B levels together with normal activin A levels identified patients with the diagnostic symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and capture the diverse array of symptoms experienced by CFS/ME patients.
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) currently presents a diagnostic dilemma because of the multi-system nature of the symptoms and the lack of a definitive serum-based diagnostic. Diagnosis is currently based on clinical case definition criteria, of which the CDC-1994/Fukuda case definition is the most frequently applied , as evidenced from the twenty case definitions identified for systematic review (SR) by Brurberg et al. . The same study also found few validation studies performed using the various diagnostic criteria, confirming the nebulous aspects of diagnosis by case definition.
Efforts to improve the rigour of CFS/ME case definitions have included an update of the 2003 Canadian Criteria to the International Consensus Criteria in 2011 [3, 4], which emphasises ME symptoms associated with cognitive and physical deficiency, with less importance on psychiatric co-morbidity and depression when compared to the Fukuda criteria. A more recent attempt to design clearer and simpler diagnostic criteria focused on post-exertional fatigue, and proposing the new name Systemic Exertion Intolerance Disease (SEID) , instead of ME and/or CFS. However, the diagnosis of the disease remains a challenge as the diagnostic criteria requires that patients experience the symptoms for at least 6 months before a definitive diagnosis can be made, leaving patients to struggle with the illness for a considerable time before being diagnosed.
Given that many patients often describe an influenza-like illness preceding the development of CFS/ME, the possibility that cytokines may provide diagnostic markers of CFS/ME has been assessed, but with little consensus as to their diagnostic utility, possibly influenced by disease-stage and other inter-patient variability. Evidence that the immune system is involved in CFS/ME is supported by low natural killer cell cytotoxicity , but to date an immune biomarker for CFS/ME has not been identified.
Given the accumulating data that activin A and B are involved in the control of inflammation and muscle mass , we undertook a cross-sectional study on the potential of activin A, activin B, and its binding protein (follistatin), as serum markers of CFS/ME, via a Melbourne clinic that works exclusively with CFS/ME patients. The activins are members of the Transforming Growth Factor β (TGFβ) family of proteins, and are dimers of subunits encoded by the INHBA (βA) and INHBB (βB) genes. The subunits dimerise to form activin A (βAβA) and activin B (βBβB) . Our previous data show that in patients admitted to intensive care units (ICU) with acute respiratory distress, survival of up to 12-months post ICU can be predicted by the measurement of activin A and B levels during the first 5 days in ICU . This may be a causal relationship, since increased activin A and activin B levels can induce a loss of muscle mass . Interestingly, activin B is involved in inflammatory-induced anaemia via regulation of hepcidin expression , a function distinct from activin A.
In addition to immune dysregulation, the loss of muscle mass suggests that the activins are potentially involved in the pathogenesis of CFS/ME, given the prominence of muscle weakness and pain as diagnostic criteria across the various case definitions. Due to these associations, in addition to symptoms spanning cognitive and gastro-intestinal functions, it was hypothesised that significant fluctuations of serum activin/follistatin levels and ratios were likely for CFS/ME patients formally diagnosed under the 2003 Canadian Criteria . Here we report the outcomes of a study of serum activin A, B and follistatin levels in blood samples from 45 patients diagnosed with CFS/ME under the 2003 Canadian Criteria, whose clinical findings formed a previously reported study and database .
Participants and setting
Participants in this study included 45 patients (40 females and 5 males: age 19–66 years) diagnosed with chronic fatigue syndrome at the CFS Discovery Clinic, a primary care community clinic that works exclusively with CFS/ME patients, located in Donvale (Victoria, Australia). Patients were diagnosed with CFS/ME if they fulfilled the Canadian Diagnostic Criteria,  as conducted by a medical practitioner and registered nurse both with 15–20 years’ experience with CFS/ME patients. For the CFS/ME cohort, length of illness ranged from 2 to 40 years. During the early phase of the study, the 2011 International Criteria for CFS/ME diagnosis were published,  but since the study had commenced participant recruitment and assessment under the 2003 criteria, the application of the 2003 criteria persisted for the duration of this study.
The study also recruited 17 healthy control participants, comprising 13 females and 4 males (age 24–60 years). Control participants were recruited via neighbouring clinics within the Doncaster district of East Melbourne, through CFS support groups and by word-of-mouth.
Research participants for this study were recruited over 2011–2012 from patients attending CFS Discovery for the first time, often after long periods of interaction with the medical profession, but no conclusive diagnosis or successful treatment. While there are theories, the cause and/or exposure that results in CFS/ME symptoms are not known. A cross-sectional (observation) study design was applied, with CFS/ME cases and healthy controls attending only once for research involvement over the 2011–2012 study period. Follow-up was provided as routine clinic attendance after the research interaction.
The assessment of patients at CFS Discovery was previously reported by Reynolds et al.  which included the protocol for orthostatic intolerance testing and results for autonomic markers of cardiac and circulatory function in CFS/ME patients, with key pathology and cytokine markers for this cohort summarised in Table 1. In addition to the formal CFS/ME diagnostic criteria, assessed by survey and physical examination, research participants were also screened for potentially confounding comorbidities. The study contained tests and clinical assessments to exclude hypothyroidism, Lupus, Fibromyalgia (FM) and Multiple Chemical Sensitivity via the physical and mental status examinations. Also, conducted on each CFS/ME and control participant were routine blood and urine tests, as described below and Table 1. Assessments of sleep patterns were ascertained via the Epworth Scale, and the DASS-36 scale applied to assess anxiety, depression and generalised stress. Recommended guidelines for CFS research also were consulted for this investigation , allowing consistent comparisons to other studies. The “Minimal Requirements” under these guidelines were generally captured by the application of the Canadian Criteria to CFS/ME status.
A patient was classified as having CFS/ME if she or he met the above criteria and all other possibilities were excluded as listed above. If a patient’s fatigue was not severe enough, or if the symptom criteria for CFS/ME were not met, he or she was classified as having idiopathic chronic fatigue. Seventeen healthy controls were also recruited and assessed exactly as described for CFS/ME participants, including orthostatic intolerance testing to screen for autonomic comorbidities. Healthy participants could not be a relative of a previous or current CFS/ME patient, or live at the same residential address.
All research participants were non-identifiable to the researchers, with individual identifiers removed from the data provided, except for a unique identification (ID) code. Because only ID codes were provided, no clinical details were attached to samples for activin/follistatin, cytokines and pathology testing, removing potential bias from test result reporting.
As a first attempt at a cross-sectional study on this CFS/ME cohort, a minimum of 30 participants for each group was planned for statistical robustness, and was achieved for the CFS/ME group. Only 17 healthy control participants were recruited within the designated study period, in spite of proactive study advertising and connection with other GP clinics in the district. In addition to the 17 recruited study controls, comparisons of serum activin/follistatin levels with a previously recruited healthy reference population (n = 141)  were also conducted for validation.
No patients were involved in the conception or design of this study, nor were patients asked for input at any stage of the project. A summary of project results is available to research patients, as stated in the participant information pack, on request.
Activin and follistatin analyses
Non-fasting blood samples were collected from patients after the 20-min standing test and the concentrations of activin A, activin B and follistatin were measured in the serum isolated from these samples. Concentrations of activin A were determined using a two-site ELISA (using antibodies supplied by Oxford Brookes University) as previously published . This assay measures both free and follistatin-bound activin A dimers and has no significant cross-reaction with other activin isoforms, such as activin B. Activin B was measured by two-site ELISA, as previously described (using antibodies supplied by Oxford Brookes University) . Follistatin concentrations were determined using an extensively validated radioimmunoassay . Mean activin/follistatin concentrations were compared between the CFS/ME and control cohorts recruited for this study. Further analyses were performed comparing the recruited CFS/ME cohort to data previously collected to calculate reference intervals for each marker.
Pathology and cytokine analyses
In addition to the blood samples collected for activin/follistatin testing, blood was also drawn for pathology testing at Australian Clinical Laboratories (Clayton, Victoria). Tests performed on each CFS/ME and control participant were routine full (complete) blood count examinations, multiple biochemical analyses that included liver and kidney function tests (with 24-h urine analysis), vitamin D (25-OH), parathyroid hormone (PTH), dehydroepiandrosterone sulfate (DHEAS), immunoglobulin (Ig) E, antinuclear antibodies (ANA) and thyroid stimulating hormone (TSH). A fasting glucose tolerance test (GTT) was performed on a separate day post clinic consultation with blood glucose and insulin measured before glucose load (75 g in 200 mL), then at 30 and 60 min post glucose load.
Chronic fatigue syndrome/myalgic encephalomyelitis and control sera were also investigated for interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-17A (IL-17A), tumour necrosis factor (TNF) and interferon-gamma (IFN-γ). The seven cytokines were simultaneously quantitated via multiplex cytometric bead array (human CBA kit, catalogue number 560484, BD Biosciences, North Ryde, NSW), with data acquisition and analysis conducted on a BD FACS Calibur (JCSMR FACS Unit, ANU, Canberra).
Comparisons of means or medians between CFS/ME and control groups were performed by independent t test or Mann–Whitney tests respectively, depending on data distribution within the sample and whether the data were continuous or ordinal, with statistical significance accepted at p < 0.05. Whether data followed a normal distribution, or not, was determined by a one-sample Kolmogorov–Smirnov (K–S) Test (SPSS version 22). Data are presented as mean ± SEM.
Chi square (χ2) was calculated to determine the statistical significance (p < 0.05) of the frequency of elevated anti-nuclear antibodies (ANA ≥ 160) between CFS/ME and study control cohorts. Receiver operating curves (ROC) were constructed using SPSS (version 22.0) software, and calculated the area under curve (AUC ± SEM) to distinguish CFS/ME from healthy control cases, using a non-parametric model.
Pathology and activin/follistatin results had no missing data. Missing data was common for the seven serum cytokines measured, and recorded as not detected (ND). Cases with missing data were excluded from the analyses. Mean ± SEM were not reported for TNF and IL-17A since protein was detected in only 2–3 samples across the CFS/ME and control cohorts.
All research participants included in this study provided full, signed consent as dictated by the guidelines of the ANU Human Research Ethics Committee (ANU-HREC). This study and associated protocols were conducted after approval by the ANU-HREC (HREC identification 2011/031).
Features of CFS/ME cohort
Routine medical and pathology analyses of 45 patients (40 females and 5 males, age 19–66 years, length of illness 2 to 40 years) diagnosed with CFS/ME under the Canadian Diagnostic Criteria, and 17 healthy controls (13 females, 4 males; age 24–60 years), were conducted. Key assay markers measured in patients diagnosed with CFS/ME were all within laboratory reference intervals (Table 1). Other routine tests included liver function tests, urea, electrolytes and creatinine, as well as erythrocyte and leukocyte markers/indices, with all results falling within the laboratory reference interval for CFS/ME and control cohorts. In addition, dihydroepiandrosteronesulphate (DHEAS), parathyroid hormone (PTH) and IgE were measured, but also showed no significant differences (p = 0.39 to 0.83, Mann–Whitney). The frequency of positive antinuclear antibody (ANA) detection (≥160), a marker for autoimmune disorders, was not statistically significant (χ2 = 2.9, df = 1, p = 0.41) between CFS/ME and control groups. Also, no significant differences between CFS/ME and healthy participants were detected for blood glucose and insulin at 30-min after glucose loading, during an oral glucose tolerance test (GTT).
Table 2 summarises the physical characteristics and symptom profile against the Canadian Criteria for the CFS/ME cohort investigated. Healthy controls were significantly taller (p = 0.002), while diastolic blood pressure and pulse rate (p < 0.05) were significantly elevated for the CFS/ME cohort. All CFS/ME participants reported the key symptoms of fatigue for greater than 6 months and post-exertional fatigue (“payback”), as well as limited activity, unrefreshing sleep, impaired thinking/speech and orthostatic intolerance (Table 2). The prevalence of other symptoms under the Canadian Criteria varied from approximately 50% of the CFS/ME cohort to less than 10% (Table 2). Participants from the healthy control cohort occasionally reported headache, gut upset or difficulties waking from sleep, but these cases were sporadic and when reported involved only 1–2 participants from the total cohort.
Activin and follistatin responses in CFS/ME and healthy control participants
Measurement of activin A, activin B and follistatin levels in serum samples from the patient and control groups were conducted using validated assays to determine the clinical utility of these proteins as biomarkers. Levels of activin B, but not activin A and follistatin, were found to be significantly elevated (p = 0.002) in patient serum samples compared to control subjects (Fig. 1). The activin B response was unique as in addition to activin A, the levels of the other cytokines measured, namely IL-2, IL-4, IL-6, IL-10, IL-17A, TNFα and IFN-γ, were not statistically significant between groups (Table 1: IL-17A was detected in 2/45 CFS/ME samples and no controls, while serum TNFα was detected in 3/45 CFS/ME samples and no controls). Despite the significant elevation of activin B, the ratio of activin B to follistatin (ActB:FST), was not found to reach significance with respect to controls (p = 0.096) (Fig. 1d).
Receiver operating curves (ROC) were calculated from the CFS/ME versus healthy study controls data for activin A, activin B, follistatin and IL-10. IL-10 was chosen since previous observations suggested a significant role for this cytokine in CFS/ME. The calculated AUC for activin B was 72.4% (0.724 ± 0.076), which was significantly independent (p = 0.010) from the 50% (0.5) AUC threshold (Fig. 2a). For activin A, follistatin and IL-10 (Fig. 2b–d), AUC results ranged from 0.467 to 0.567 and were not significant (p = 0.43–0.70).
CFS/ME activin analyses in relation to a normal reference population
Prior to this study, 141 healthy volunteers were recruited by de Kretser et al.  to determine the serum reference intervals for activin A, activin B and follistatin, including the ratios of the activins A and B to follistatin (ActA:FST and ActB:FST) in a normal population (referred to herein as reference data to distinguish it from the study control group). This reference data was established using the same validated assays used to measure the samples obtained for this study. When comparing the data to this reference range, CFS/ME patients had a significantly higher activin B (p < 0.0001), but not activin A levels (Fig. 3a, b), suggesting an important relationship between activin B and CFS/ME. The control group data were within the reference range.
Comparisons to the reference data also showed that follistatin levels were significantly lower in the CFS/ME group (p < 0.0001) (Fig. 3c), and therefore, both activin A:follistatin (ActA:FST, p < 0.015) and activin B:follistatin (ActB:FST, p < 0.0001) ratios were significantly higher in CFS/ME patients (Fig. 3d, e), with a greater difference seen for the activin B/follistatin ratio. Concordantly, activin B levels relative to activin A levels (ActB: ActA ratio) were significantly elevated in CFS/ME patients (p < 0.0001) compared to the reference data (Fig. 3f). These data show that activin B levels, as well as activin A or B to follistatin ratios, were elevated above the normal range in patients with CFS/ME.
Chronic fatigue syndrome/myalgic encephalomyelitis is a disorder that causes unexplained, persistent and sometimes disabling fatigue, with no definitive diagnostic tests available. Patients with this illness experience frustration due to health care provider difficulties in reaching a diagnosis of CFS/ME, compounded by the range and variation of the available diagnostic criteria . It is estimated that around 0.4% of people world-wide suffer from CFS/ME  and the Centres for Disease Control and Prevention in the USA has declared it a priority disease, along with TB and AIDS. With the majority of affected patients not receiving the correct diagnosis, and therefore never receiving the proper medical care for their illness , there is a pressing need for a diagnostic biomarker to assist these patients.
The results of this study establish that patients with serum activin B levels significantly elevated above the established reference range associate with the symptoms of CFS/ME, in contrast to serum activin A. Our data, therefore, indicate that the pattern of elevated serum activin B together with normal activin A identified a group of patients with CFS/ME, as defined by the 2003 Canadian Criteria. Consequently, this pattern of serum activin A and B represents a diagnostic marker, in contrast to the failure of other cytokines to define patients with CFS/ME. This observation was further confirmed by the finding that serum activin A and B levels in the study control group, recruited at the same time as the CFS/ME participants, were not statistically different from the established reference ranges . The altered patterns of activins contrast with the numerous studies of a wide range of serum markers that have been measured previously seeking a diagnostic test for CFS/ME [2–6]. Serum and blood markers available via pathology laboratories generally fall within the assay reference interval for CFS/ME patients, as observed for the participants of this study.
The repeat of this study with larger patient and control cohorts will be a priority for the future, as will the investigation of activin/follistatin in relation to other forms of fatigue. Bias was minimised through the coding regime used to protect research participant confidentiality. No clinical notes or personal details were attached to the activin samples at any time, and the researchers had no contact with patients directly or with their medical histories during the planning of the study, and interrogation of the data.
Prior studies on the value of cytokines as biomarkers is divided, with some studies promoting the efficacy of cytokine profiles when considering onset characteristics and longitudinal studies [17, 18]. In contrast, reviews of the literature concluded that CFS/ME does not involve immune dysfunction , a conclusion supported by experimental studies that included results from CFS/ME patients in the context of exercise and sleep deprivation . It was noted that interleukin 10 (IL-10) provided diagnostic value, but required spinal fluid samples from CFS/ME patients .
Transforming growth factor-beta (TGF-β) likewise has been mentioned as a significant marker [22, 23]. TGF-β modulation is also of note because of its role in NK-cell regulation and suppression , with NK-cell dysfunction a consistent CFS/ME observation for 25 years . TGF-β1 inhibited NK cell DNA synthesis and production of cytokines, as well as weakly inhibited cytotoxic activity , with the inhibition of NK cell activity by TGF-β later found to involve the inhibition of mTOR kinase signalling, including post IL-15 stimulation .
However, TGF-β1 has a history of challenges in terms of biomarker development, involving the need for special blood collection methods and the removal of platelets prior to assay, as well as early reports of up to tenfold variation in disease studies, in comparison to control subjects [28–30]. TGF-β1 variation due to exogenous and endogenous factors, therefore, limited its diagnostic reliability. This is not true for activin B. Activin B levels do not change with respect to age, sex, BMI, ethnicity, smoking, allergies or type of medication  and to date, activin B levels have not been reported to be elevated or reduced in other diseases. Together with an established reference interval [8, 14], activin B has the potential to be a biomarker of clinical utility for CFS/ME, once validated on additional cohorts and other clinical criteria .
Activin A is a known modulator of the inflammatory cascade with its role as a pro-inflammatory cytokine discovered following its rapid elevation after lipopolysaccharide (LPS) was administered to mice , and there is evidence that activin B exerts actions similar to activin A, for example in muscle wasting and renal injury [32, 33]. However, others have shown that activin B exerts distinct functions to activin A, such as regulating hepcidin expression during the pathogenesis of inflammation-induced anaemia via Smad 1/5/8 signalling, while activin A exerts its actions through Smad 2/3 signalling . Our data shows that levels of activin A and inflammatory cytokines were not elevated in CFS/ME patients, indicating an absence of underlying inflammation in these patients. The observed elevation of activin B levels, as well as elevated activin to follistatin ratios, indicates an increased systemic bioavailability of activins; however, the mechanisms by which activin B is causally linked requires further investigation.
The finding of an elevated serum activin B level also raises the possibility that treatment with follistatin may be of value in the management of patients with CFS/ME, since follistatin, in addition to blocking the actions of activin A, also can block the actions of activin B. Further, treatment with follistatin has the potential advantage that in addition to attenuating the actions of the activins, it can also block the actions of myostatin, thus enhancing muscle mass .
Given the inability to clearly diagnose CFS/ME by the measurement of other cytokines, the demonstration that the measurement of activins A/B and follistatin enabled the identification of a population of CFS/ME patients, diagnosed via the Canadian criteria, is significant. These results propose that measurements of the activins and follistatin will be of value in separating patients with CFS/ME from other disorders that also cause fatigue. These data strongly suggest the need for a larger prospective study of CFS/ME patients to determine whether the detection of elevated serum activin B and normal activin A levels can predict the subsequent course for such patients.
chronic fatigue syndrome
Systemic Exertion Intolerance Disease
intensive care unit
enzyme-linked immune-sorbent assay
thyroid stimulating hormone
glucose tolerance test
tumour necrosis factor
standard error of the mean
- χ2 :
receiver operating curve
area under curve
transforming growth factor-beta
natural killer (cells)
mammalian target of rapamycin
Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953–9.
Brurberg KG, Fønhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open. 2014;4:2.
Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7–115.
Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327–38.
Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313:1101–2.
Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, et al. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS ONE. 2010;5:e10817.
Hedger MP, de Kretser DM. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013;24:285–95.
de Kretser DM, Bensley JG, Pettila V, Linko R, Hedger MP, Hayward S, et al. Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Crit Care. 2013;17:R263.
Chen JL, Walton KL, Al-Musawi SL, Kelly EK, Qian H, La M, et al. Development of novel activin-targeted therapeutics. Mol Ther. 2015;23:434–44.
Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, Roth MP, et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012;120:431–9.
Reynolds GK, Lewis DP, Richardson AM, Lidbury BA. Comorbidity of postural orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian cohort. J Intern Med. 2014;275:409–17.
Jason LA, Unger ER, Dimitrakoff JD, Fagin AP, Houghton M, Cook DB, et al. Minimum data elements for research reports on CFS. Brain Behav Immun. 2012;26:401–6.
Knight PG, Muttukrishna S, Groome NP. Development and application of a two-site enzyme immunoassay for the determination of ‘total’ activin-A concentrations in serum and follicular fluid. J Endocrinol. 1996;148:267–79.
Ludlow H, Phillips DJ, Myers M, McLachlan RI, de Kretser DM, Allan CA, et al. A new ‘total’ activin B enzyme-linked immunosorbent assay (ELISA): development and validation for human samples. Clin Endocrinol. 2009;71:867–73.
O’Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod. 1999;14:827–32.
Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999;159:2129–37.
Stringer EA, Baker KS, Carroll IR, Montoya JG, Chu L, Maecker HT, et al. Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. J Transl Med. 2013;11:93.
Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol. 2004;135:294–302.
Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res. 2003;55:79–90.
Nakamura T, Schwander S, Donnelly R, Cook DB, Ortega F, Togo F, et al. Exercise and sleep deprivation do not change cytokine expression levels in patients with chronic fatigue syndrome. Clin Vaccine Immunol. 2013;20:1736–42.
Peterson D, Brenu EW, Gottschalk G, Ramos S, Nguyen T, Staines D, et al. Cytokines in the cerebrospinal fluids of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Mediat Inflamm. 2015. doi:10.1155/2015/929720.
Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH, et al. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol. 1997;17:160–6.
Chao CC, Janoff EN, Hu SX, Thomas K, Gallagher M, Tsang M, et al. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine. 1991;3:292–8.
Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, et al. Dendritic cell regulation of NK-cell responses involves lymphotoxin-alpha, IL-12, and TGF-beta. Eur J Immunol. 2015;45:1783–93.
Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403–10.
Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol. 1995;155:1066–73.
Viel S, Marcais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 2016;9:19.
Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer. 1994;73:2275–9.
Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care. 1996;19:1113–7.
Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000;11(1–2):133–45.
Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA. 2007;104:16239–44.
Chen JL, Walton KL, Winbanks CE, Murphy KT, Thomson RE, Makanji Y, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014;28:1711–23.
Fang DYP, Lu B, Hayward S, de Kretser DM, Cowan PJ, Dwyer KM. The role of activin A and B and the benefit of follistatin treatment in renal ischemia-reperfusion injury in mice. Transplant Direct. 2016;2:e87.
Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009;39:283–96.
BAL took a lead role in writing the manuscript. He was a project leader for the work presented in the manuscript, as well as had a primary role in the study design and analyses. BK generated the figures and reviewed/edited the manuscript. DPL provided the patient serum samples and clinical data for the study, as well as qualitative advice on research participation that assisted the study design. SH conducted the ELISA assays of the serum samples and reviewed the manuscript. HL provided the antibodies for the ELISA assays and reviewed the manuscript. MPH reviewed the assay data and edited the manuscript. DdK initiated the project and coordinated the assessment of activins and follistatin in CFS/ME patients, and was involved with the writing of the manuscript. All authors read and approved the final manuscript.
We thank the Alison Hunter Memorial Foundation (AHMF) for funding and supporting this study. Thanks also to Edwina Privitera and CFS Discovery staff, Guifang Shang for running the cytokine assays and Gemma Reynolds for assistance with the data analyses. This work also was supported by grants (to MPH and DdK) from the National Health and Medical Research Council of Australia, and by the Victorian Government’s Operational Infrastructure Support Program. We thank Oxford Brookes University for kindly supplying the antibodies used in the activin assays described herein. Finally, many thanks to the CFS Discovery patients who supported this study as research participants.
DdK is a founder of Paranta Biosciences, a company developing follistatin for clinical use, and a shareholder in the company, with a patent 2014366827 licensed to Paranta Biosciences Ltd. BAL reports grants from the Alison Hunter Memorial Foundation, and has a research relationship with Paranta Biosciences via BK and DdK, and together they have applied for subsequent research grants together. He has no financial connections or interests with Paranta Biosciences. BK was a salaried employee of Paranta Biosciences Limited during the conduct of the study, but did not draw personal fees from Paranta Biosciences Limited, outside the submitted work. SH is employed by the Hudson Institute, being funded by grants from National Health and Medical Research Council, held by DdK and MPH during the conduct of the study. DPL is a general practitioner who sees patients with CFS/ME, and was involved as a co-investigator on the Alison Hunter Memorial Foundation grant held by BAL. He is the medical practitioner whom assessed and managed the care of the research participants. He is the director of CFS Discovery. HL has nothing to disclose. MPH reports grants from National Health and Medical Research Council, during the conduct of this study and others linked to Paranta Biosciences, outside the submitted work. He serves on the Scientific Advisory Board to Paranta Bisciences, a company that is developing the activin-binding protein (follistatin) for therapeutic use, and holds shares in the company.
Availability of data and materials
The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.
Consent for publication
No individual data is presented, only anonymous aggregated results calculated from non-identifiable raw participant data.
Ethics approval and consent to participate
This study and associated protocols were conducted after approval by the Australian National University Human Research Ethics Committee (ANU-HREC) (HREC identification 2011/031). All research participants consented to having their anonymous data included in the analyses reported herein.
The Alison Hunter Memorial Foundation (AHMF), National Health and Medical Research Council of Australia, and the Victorian Government’s Operational Infrastructure Support Program. The funding bodies acknowledged above had no input into the design or conduct of this study.